DE3868438D1 - Cyclosporin enthaltende pharmazeutische zubereitung. - Google Patents

Cyclosporin enthaltende pharmazeutische zubereitung.

Info

Publication number
DE3868438D1
DE3868438D1 DE8888305138T DE3868438T DE3868438D1 DE 3868438 D1 DE3868438 D1 DE 3868438D1 DE 8888305138 T DE8888305138 T DE 8888305138T DE 3868438 T DE3868438 T DE 3868438T DE 3868438 D1 DE3868438 D1 DE 3868438D1
Authority
DE
Germany
Prior art keywords
pharmaceutical preparation
preparation containing
containing cyclosporine
cyclosporine
cyclosporins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8888305138T
Other languages
German (de)
English (en)
Inventor
Kozo Kurihara
Masaru Murano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of DE3868438D1 publication Critical patent/DE3868438D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE8888305138T 1987-06-04 1988-06-06 Cyclosporin enthaltende pharmazeutische zubereitung. Expired - Lifetime DE3868438D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14070387 1987-06-04

Publications (1)

Publication Number Publication Date
DE3868438D1 true DE3868438D1 (de) 1992-03-26

Family

ID=15274767

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888305138T Expired - Lifetime DE3868438D1 (de) 1987-06-04 1988-06-06 Cyclosporin enthaltende pharmazeutische zubereitung.

Country Status (10)

Country Link
US (1) US5051402A (forum.php)
EP (1) EP0294239B1 (forum.php)
JP (1) JP2577049B2 (forum.php)
AT (1) ATE72629T1 (forum.php)
AU (1) AU607506B2 (forum.php)
CA (1) CA1325973C (forum.php)
DE (1) DE3868438D1 (forum.php)
ES (1) ES2033429T3 (forum.php)
GR (1) GR3004199T3 (forum.php)
HK (1) HK28097A (forum.php)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH07111785B2 (ja) 1990-01-19 1995-11-29 富士通株式会社 光ディスク
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
FR2670629B1 (fr) * 1990-12-17 1995-03-10 Moving Magnet Tech Actionneur electromagnetique monophase rotatif.
DE69222150T2 (de) * 1991-01-25 1998-01-15 Fujisawa Pharmaceutical Co Prozess zur produktion von cyclosporin-a und/oder c
HK1004520A1 (en) * 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
DK0756489T3 (da) * 1994-06-01 1999-12-06 Yuhan Corp Cyclosporinholdigt præparat og fremgangsmåde til fremstillingen af dette
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
JP2007056045A (ja) * 1995-05-26 2007-03-08 Nobaruteisu Fuaama Kk サイクロデキストリン組成物
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
KR20050084502A (ko) 1997-01-30 2005-08-26 노파르티스 아게 오일을 함유하지 않은 사이클로스포린 a 함유 제약 조성물
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
DE69840586D1 (de) 1997-10-08 2009-04-02 Isotechnika Inc Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1435910B9 (en) * 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
SI1436321T1 (sl) 2001-10-19 2006-12-31 Isotechnika Inc Sinteza analogov ciklosporina
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
DE602004031356D1 (de) 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
US7691812B2 (en) 2004-11-04 2010-04-06 Trustees Of The University Of Pennsylvania Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
FI118537B (fi) * 2006-03-08 2007-12-14 Kuopion Yliopisto Menetelmä syklodekstriinin kompleksoitumisen lisäämiseksi
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
AU2016203191B2 (en) * 2006-07-25 2018-03-01 Allergan, Inc. Cyclosporin compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
MX2010003364A (es) 2007-10-08 2010-07-06 Lux Biosciences Inc Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor.
US20100016219A1 (en) * 2008-07-19 2010-01-21 Jerry Zhang Ophthalmic compositions containing solubilized cyclosporin
MX338355B (es) 2009-06-09 2016-04-13 Aurinia Pharmaceuticals Inc Sistemas de suministro de farmaco topico para uso oftalmico.
WO2013003827A2 (en) * 2011-06-29 2013-01-03 Allergan, Inc. Macrogol 15 hydroxystearate formulations
US20180161449A1 (en) * 2015-05-29 2018-06-14 Oculis Ehf Formation of cyclosporin a/cyclodextrin nanoparticles
CN105997863B (zh) * 2016-07-21 2018-09-04 河南省眼科研究所 环孢素a滴眼液及其制备方法
CN110177576B (zh) 2016-11-29 2023-08-11 奥库里斯公司 用于眼用活性药物成分递送的固体环糊精复合物的制备
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
MX2021015767A (es) 2019-07-01 2022-01-27 Oculis SA Metodo para estabilizar el ph de una composicion acuosa que comprende un farmaco.
CN112724200B (zh) * 2019-10-28 2022-09-27 上海云泽生物科技有限公司 一种稳定环孢霉素a的稀释液及其应用
CN116390762A (zh) 2020-11-09 2023-07-04 思凯制药有限公司 固体环孢菌素a和包含其的分散组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
PH19156A (en) * 1982-02-01 1986-01-15 Sandoz Ltd Dihydrocyclosporin d in the treatment of multiple sclerosis
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3580717D1 (de) * 1984-08-02 1991-01-10 Sandoz Ag Pharmazeutische anwendung von (nva)2-cyclosporine.

Also Published As

Publication number Publication date
JP2577049B2 (ja) 1997-01-29
JPS6485921A (en) 1989-03-30
AU1738688A (en) 1988-12-22
ATE72629T1 (de) 1992-03-15
HK28097A (en) 1997-03-06
AU607506B2 (en) 1991-03-07
ES2033429T3 (es) 1993-03-16
EP0294239B1 (en) 1992-02-19
CA1325973C (en) 1994-01-11
US5051402A (en) 1991-09-24
EP0294239A1 (en) 1988-12-07
GR3004199T3 (forum.php) 1993-03-31

Similar Documents

Publication Publication Date Title
DE3868438D1 (de) Cyclosporin enthaltende pharmazeutische zubereitung.
NO883926L (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
ES2033086T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica.
HK86593A (en) Pharmaceutical compositions containing cyclosporins
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
ATE203411T1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
SE9503143D0 (sv) New preparation
MY101593A (en) Sustained release preparation.
ATE109145T1 (de) Heterozyklische acylaminothiazolderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
DK1027053T3 (da) Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser
PT88539A (pt) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
DE3776620D1 (de) 3-propenylcephemderivate, ihre herstellung, zwischenverbindungen, pharmazeutische praeparate und anwendung.
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
ATE70445T1 (de) Pharmazeutische praeparate.
RU96114157A (ru) Способ лечения острых отравлений
SE8902458L (sv) Laekemedelskomposition
DE58904108D1 (de) Arzneimittel.
RU96106437A (ru) Способ лечения сухой остаточной полости после перенесенного абсцесса легкого
ES2060057T3 (es) Soluciones acuosas conteniendo proteina.
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
DE59007260D1 (de) Pharmazeutische zubereitung zur rektalen verabreichung.
JPS6461429A (en) Remedy for cancer
DE3865642D1 (de) Pharmazeutische zubereitung zur cholelitholyse.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8328 Change in the person/name/address of the agent

Free format text: STREHL, SCHUEBEL-HOPF & PARTNER, 80538 MUENCHEN